Anzeige
Mehr »
Freitag, 24.10.2025 - Börsentäglich über 12.000 News
Gold über 4.000 US-Dollar - Canary Gold startet Multi-Front-Exploration in Brasiliens neuem Gold-Hotspot
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C7A5 | ISIN: FR0012634822 | Ticker-Symbol: 4RD
München
24.10.25 | 08:04
4,280 Euro
-0,70 % -0,030
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MAAT PHARMA SA Chart 1 Jahr
5-Tage-Chart
MAAT PHARMA SA 5-Tage-Chart
RealtimeGeldBriefZeit
4,2004,34023:00

Aktuelle News zur MAAT PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.10.MaaT Pharma stock jumps 11% after DSMB clears Phase 2b trial to continue5
07.10.MaaT Pharma's MaaT033 For Allo-HSCT Patients Clears Second DSMB Safety Review In Phase 2b Trial2
07.10.MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT232The DSMB conducted an unblinded safety review of data from the first 120 enrolled patients and identified no safety concerns and no excessive mortality related to MaaT033 as of today. The...
► Artikel lesen
MAAT PHARMA Aktie jetzt für 0€ handeln
17.09.MaaT Pharma Publishes Its Half Year 2025 Results and Provides a Business Update423Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results showed a 62% gastrointestinal overall response rate at Day 28 and 1-year expected Overall...
► Artikel lesen
30.07.MaaT Pharma: €37.5 Million EIB Loan Secured To Advance Cancer Therapies3
28.07.MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology489Tranche-based financing to support clinical development for the Company's late-stage assets in hemato-oncology including Xervyteg currently under review for potential approval by the EMA and MaaT033...
► Artikel lesen
24.07.MaaT Pharma: Half-year Report to the Liquidity Contract With Kepler Cheuvreux278Regulatory News: MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing...
► Artikel lesen
07.07.MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital289Article 223-16 of the General Regulations of the Financial Markets Authority (AMF Autorité des Marchés Financiers) Regulatory News: MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage...
► Artikel lesen
02.07.MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg in acute Graft-versus Host Disease in Europe491MaaT Pharma and Clinigen signed exclusive long-term licensing and distribution agreement and commercial supply agreement for Xervyteg(MaaT013), its first in class treatment proposed for patients...
► Artikel lesen
24.06.MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting343Regulatory News: MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies(MET) dedicated to enhancing...
► Artikel lesen
19.06.MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025477Marketing Authorization application of Xervyteg (MaaT013) in acute graft-versus-host-disease submitted to the European Medicines Agency (EMA) in June 2025 MAA could be expected in H2 2026...
► Artikel lesen
13.06.MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg at the EHA Congress Validating High Efficacy Observed in Pivotal ARES Study in Acute Graft-versus-Host Disease404Oral presentation highlights updated data in Early Access Program (EAP) for 173 patients with acute Graft-vs-Host Disease (aGvHD) treated with Xervyteg Independent dataset from EAP reinforces...
► Artikel lesen
02.06.MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg (MaaT013) in Acute Graft-versus-Host Disease448MaaT Pharma submitted today a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its product candidate MaaT013, under the registered brand name of Xervyteg Xervyteghas...
► Artikel lesen
14.05.MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress344Oral presentation will highlight updated data in Early Access Program (EAP) for 173 patients with acute Graft-vs-Host Disease (aGvHD) treated with MaaT013. Poster presentation selected...
► Artikel lesen
14.05.MaaT Pharma to Hold Annual General Meeting on June 20, 2025418Regulatory News: MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing...
► Artikel lesen
13.05.MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025389Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results showed a 62% gastrointestinal overall response rate at Day 28 and 1-year expected Overall...
► Artikel lesen
12.05.MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)408Regulatory News: MaaT Pharma(EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing...
► Artikel lesen
29.04.AACR 2025: MaaT Pharma, the gut microbiome, and immuno-oncology-
28.04.MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034355Regulatory News: MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing...
► Artikel lesen
14.04.Availability of MaaT Pharma's 2024 Universal Registration Document (URD)328Regulatory News: MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing...
► Artikel lesen
Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1